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THE effect ofglycosaminoglycans (GAGs) on the prolifera-
tion of smooth muscle cells (SIC) and fibroblasts was as-
sessed by culturing cells with or without GAGs. Porcine
heparan sulphate (HS) inhibited proliferation in a dose
dependent manner. At 167 #g/ml of HS this reached 88%
and 72% inhibition of SMC and fibroblast growth, respec-
tively. Pig and beef mucosal heparins also blocked prolif-
eration, but to a lesser extent. In contrast, beef lung
heparin, chondroitin sulphate, and dermatan sulphate
failed to block growth factor induced proliferation.
Continuous presence of HS was not required, suggesting
that the inhibitory effects resulted from a direct effect on
the cell rather than an interaction of the GAG with growth
factors. The mechanism by which GAGs inhibit prolifera-
tion will be addressed in future studies.
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Introduction
Heparin has been reported to inhibit the growth
of cells in vitro.
1-s However, due to its anticoagulant
properties its value as a therapeutic agent in
preventing the aberrant cell proliferation, which is
the hallmark of a variety of diseases such as
atherosclerosis and pulmonary fibrosis, is severely
glycosaminoglycans limited. This limitation would
not apply for (GAGs) such as heparan sulphate
(HS) which are not very strong anticoagulants.
6
Glycosaminoglycans are linear anionic poly-
electrolytes composed of alternating glucosamine
and uronic acid sugars.
7 HS, for example, contains
uronic acids that are mostly glucuronic with small
amounts of iduronic present, the glucosamine units
are largely N-acetylated with a small number being
N-sulphated. In heparin, the uronic acids differ
from those found in HS, as there is more iduronic
acid than glucuronic, also the glucosamine pattern
is reversed such that the extent of N-sulphation is
largely increased over the N-acetylation.
6
To determine whether GAGs other than heparin
can prevent cell proliferation, a series of GAGs
including HS, dermatan sulphate, and chondroitin
sulphate, were examined and tested for their ability
to inhibit the replication of mesenchymal cells
triggered by growth factors. Heparin was used for
comparative purposes. The studies reveal that a
porcine HS with low anticoagulant activity had a
significant inhibitory effect on growth factor
induced proliferation of Nor-10 smooth muscle
cells (SMC), NIH 3T3 fibroblasts, and U-2 human
osteosarcoma cells. The continuous presence of HS
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was not necessary to prevent the growth factor
induced proliferation of cells. This suggested that
the GAG was acting directly on the target cell,
rather than merely binding to, and removing,
growth factors in the media.
Materials and Methods
Reagents: GAGs used in these studies were obtained
from the following sources: porcine mucosal
heparin (PMH) from Institut Choay (Paris, France);
bovine mucosal heparin (BMH), porcine pancreatic
heparan sulphate (HS), and bovine mucosal
dermatan sulphate (DS) from Opocrin S.p.A.
(Modena, Italy); bovine lung heparin (BLH) from
the Upjohn Company (Kalamazoo, MI); and bovine
trachea chondroitin sulphate C (CS) from The
Sigma Company (St Louis, MO). Human platelet
derived growth factor (PDGF) and porcine
transforming growth factor-fl (TGFfl) were ob-
tained from R and D Systems (Minneapolis, MN).
All tissue culture reagents were obtained from
GIBCO Laboratories (Grand Island, NY).
Cell culture and proliferation assay: Proliferation assays
were performed with a murine smooth muscle cell
line (Nor-10), murine NIH 3T3 fibroblasts and a
human osteosarcorna cell line (U-2). Nor-10 and
U-2 cells were obtained from ATCC (Rockville,
MD); NIH 3T3 cells were the kind gift of Dr
Howard Young (NCI, Frederick, MD). Cells were
cultured in Dulbecco’s Modified Eagle’s Medium
(DME) with 5% foetal bovine serum (FBS),
penicillin (100 units/ml), streptomycin (100 #g/ml)
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and glutamine (2 mM) in an atmosphere of 5% CO2
in air at 37C.
The cell proliferation assay used in these studies
is a simple, reproducible, non-radioactive assay
modified as follows from Kamijo et al. Cells were
plated in 96-well plates at a density of 4200 cells per
well in DME supplemented with 1% foetal bovine
serum (FBS). After 18 h, GAGs were added in
triplicate in medium containing 10% FBS or
purified growth factors (PDGF at 5 ng/ml or TGFfl
at 15 ng/ml). Medium containing 10% FBS, without
GAGs, and medium without FBS served as positive
and negative controls, respectively. After 72 h cells
were stained with crystal violet, solubilized with
SDS, and the optical density (O.D.) was measured
with a Dynatech (Chantilly, VA) ELISA plate
reader. The maximal O.D. for cells grown in the
presence of medium containing 10% FBS ranged
from 0.3 to 1.5. The O.D. for freshly plated cells
was comparable to that of cells cultured with
growth inhibitory GAGs, ranging from 0.02 to
0.07. Percent inhibition was calculated as 1 (O.D.
lysate of cells treated with growth factors and
GAGs/O.D. lysate of cells treated with growth
factors alone) x 100. All experiments were repeated
a minimum of three times. The increase in O.D.
values is not due to an increase in cell size but in
actual cell number as counted by a haemacytometer
in response to various concentrations of FBS.
To determine whether the continuous presence
of the GAG was necessary for inhibition of cell
proliferation, cells were cultured for 18 h with
GAGs, after which the medium was replaced with
medium containing 10% FBS, 15 ng/ml TGF// or
5ng/ml PDGF. Cells were incubated for an
additional 48 h, after which time they were stained
and O.D. determined.
Results
Evaluation of the effect of GAGs on SMC proliferation: A
subset ofGAGs was tested for their effects on SMC
proliferation (Table 1). Of the GAGs tested, HS
caused the greatest inhibition of growth followed
by PMH and BMH. At 167/,g/ml, HS inhibited --" 88% of the growth factor activity in 10% FBS,
whereas PMH and BMH inhibited growth by 72% d
and 41%, respectively. In contrast, BLH, CS, and 9].
DS failed to diminish the growth factor induced
proliferation of SMC (data not shown). HS
exhibited dose dependent inhibition of SMC
growth (Fig. 1). Half maximal inhibition of
proliferation was noted at 35-40/g/ml. Since HS
and PMH caused the greatest amount of growth
inhibition, subsequent studies focused on these
GAGs. HS consistently has a greater inhibitory
effect on SMC proliferation than PMH even at
levels as low as 20 #g/ml. The etCfects of GAGs on
Table 1. Effect of GAGs on the proliferation of Nor-10 SMC,
NIH 3T3 fibroblasts and U2 osteosarcoma cells
Treatmentb Cell number
O.D. ___
S.D. Inhibition
Nor-10 cells
No GAG 0.70 + 0.04
HS 0.09 + 0.02 88%
PMH 0.20 __+ 0.01 72%
BMH 0.42 +_ 0.03 41%
BLH 0.68 __+ 0.06 0%
3T3 cells
No GAG 0.80 __+ 0.05
HS 0.41 + 0.04
PMH 0.59 __+ 0.06
U2 cells
No GAG 0.27 ___
0.00
HS 0.02 _+ 0.00
PMH 0.22 _+ 0.03
49%
26%
91%
17%
Cells were cultured in medium containing 10% FBS in the
presence or absence of GAGs. After 72 h, cell number was
determined by measuring the optical density (O.D.) -t- standard
deviation (S.D.) of cell preparations stained with crystal violet.
b GAGs were tested in triplicate at 167 #g/ml.
cell proliferation was not a result of cytotoxicity of
the GAGs (data not shown).
Effect ofHS andPMH on proliferation of3T3 )qbroblasts and
U-2 osteosarcoma cells: To determine whether the
growth inhibitory effects of HS and PMH were
specific for SMC, the authors examined whether
growth factor induced proliferation of other cell
types could be suppressed by GAG treatment. As
shown in Table 1, the growth of 3T3 fibroblasts
was inhibited by the addition of either HS or PMH
(167/tg/ml). It was also found that U-2 osteosarco-
ma cells were more sensitive to inhibition by HS
(167/g/ml) than NIH 3T3 cells or SMC.
Inhibitory effect ofHS on the proliferation ofSMC in response
to purified growth factors" To confirm that the growth
inhibitory effects of HS are effective on purified
10% FBS
50 100 150 200 250 300 350
HS (#g/ml)
FIG. 1. Dose response of HS on Nor-10 SMC proliferation. Cells were
treated with varying concentrations of HS as described in Materials and
methods. O.D. was calculated as a mean of triplicate determinations
_-+S.D. 10% FBS line represents level of Nor-10 growth in the absence
of GAG treatment.
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proliferation
Treatmentb Cell number
O.D. __+ S.D. Inhibition
TGF/ alone 0.65 + 0.07
TGF/ + HS 0.31 __+ 0.05 53%
PDGF alone 0.42 +__ 0.06
PDGF + HS 0.12 _+ 0.03 72%
Cells were cultured in the presence or absence of growth
factors with or without HS. After 72 h, cell number was
determined by measuring the optical density (O.D.) -I- standard
deviation (S.D.) of cell preparations stained with crystal violet.
b GAGs were tested in triplicate at 167/g/ml, TGF/Y and PDGF
were 15 ng/ml and 5 ng/ml, respectively.
growth factors, the regulatory effects of HS on the
proliferation of SMC triggered by a TGFfl
(15ng/ml) and eDGF (5ng/ml) (Table 2) was
tested. The addition of HS (100/.tg/ml) to cultures
of Nor-10 cells given PDGF or TGF/ blocked the
level of proliferation by 72% and 53%, respectively.
This confirmed that the growth inhibitory effects of
HS were not merely a phenomenological effect of
serum administration or the adsorption of essential
nutrients to the GAGs.
Effects oflimited exposure ofSMC to HS ongrowth inhibition:
In an attempt to elucidate the mechanism of growth
inhibition by HS, studies were aimed at determining
whether HS acts by binding to growth factors and
preventing their interaction with cell surface
receptors or by exhibiting a direct effect on the
target cell. To test this, SMC were cultured in the
presence or absence of HS for 18 h after which, the
medium was aspirated and replaced with medium
containing growth factor (either 10% FBS or
purified PDGF (2.5 ng/ml) in 1% FBS (Table 3)).
Table 3. Effect of pre-treatment of Nor-10 SMC with HS on
proliferation induced by FBS or PDGF
Treatmentb Cell number
O.D. __+ S.D. Inhibition
FBS alone 1.48 +_ 0.06
FBS + HS (3/g/ml) 1.1 5 _+ 0.06 22%
(33 #g/ml) 1.02 _+ 0.10 31%
(167 /g/ml) 0.13 _+ 0.07 91%
PDGF alone 0.36 _+ 0.04
PDGF + HS (167/g/ml) 0.15 _+ 0.01 57%
Cells were cultured in the presence or absence of HS for 18 h
after which the medium was replaced with medium containing
growth factors (10% FBS or 5 ng/ml PDGF) without GAGs.
Cells were incubated for an additional 48 h. Cell number was
determined by measuring the optical density (O.D.) -t- standard
deviation (S.D.) of cell preparations stained with crystal violet.
b Proliferation was tested in triplicate.
Heparan inhibition ofproliferation
The amount of inhibition induced by HS after 18 h
of exposure ranged from 30% (33 #g/ml HS) to near
100% (167/.tg/ml). Further experiments examined
the effects of 18, 4, and 1 h pre-treatment of SMC.
These experiments revealed that 4 h pre-treatment
caused approximately 50% the inhibition seen at
18 h pre-treatment while 1 h pre-treatment had no
inhibitory effect. Hence, the brief exposure of cells
to HS (less than 4 h) did not halt the inhibitory
activities of the GAG, suggesting that HS exhibits
its effects by interaction with the target cell rather
than blocking the interaction ofgrowth factors with
their receptors.
Discussion
Glycosaminoglycans have been examined pre-
viously for their effects on cell proliferation.
9-12 A
majority of these studies demonstrated that heparin
moieties cause the greatest growth inhibition. The
present authors, on the other hand, found an HS
moiety that inhibits the proliferation of SMC,
fibroblasts and an osteosarcoma cell line to a greater
extent than any of the other GAGs tested, including
heparin. Other HS moieties capable of inhibiting
growth have been observed by other investigators.
Reilly et al.
3 reported an HS species capable of
inhibiting SMC growth. This HS was 40 times more
active than heparin and was found to be uniquely
placed on the cell surface of post-confluent SMC
but not on exponentially growing cells, suggesting
a possible role for HS as an endogenous mediator
of proliferation. Recently, Benitz et a1.13 isolated an
endothelial HS proteoglycan that was a potent
inhibitor of SMC growth. The inhibitory activity
of this HS was 1000 times greater than the tested
heparin preparation. It is possible that there is a
specific structural determinant of the HS used in
both our studies and in these latter published
studies, that confers a growth inhibitory property.
HS and heparin have certain structural similar-
ities, including alternating D-glucuronic acid and
N-acetyl-D-glucosamine units,6’14 as well as similar
biosynthetic pathways. Correlations between hepar-
in’s growth inhibitory activity and structure have
been made previously. 1’1s-iv Wright et al.,s
examining the growth inhibitory activity of heparin
on rat vascular smooth muscle cells (VSMC), calf
VSMC, and rat cervical epithelial cells, found that
hexasaccharide fragments were antiproliferative for
all three cell types, while a synthetic pentasaccharide
inhibited only the rat and calf VSMC. The largest
anti-proliferative effects were observed with dode-
casaccharide and larger fragments. An inter-
dependence between size and charge was also
observed. In addition, the degree of sulphation
correlated positively with the anti-proliferative
activity such that completely desulphated heparin
Mediators of Inflammation. Vol 2.1993 301I. E. Silber et al.
failed to inhibit cell growth.
16 In contrast, the 2-0
sulphate glucuronic moiety was found not to be
required for antiproliferative activity.
12 Thus,
sulphation and saccharide components may be
critical elements in the anti-proliferative nature of
GAGs.
Several contradictory studies have examined the
growth modulatory interactions of GAGs and
growth factors. Dupuy et al.
11 found that an
unfractionated pig mucosal heparin (PMH) en-
hanced the growth inducing effects of PDGF on
fibroblasts. This was also observed with FGF and
EGF, but to a lesser extent. Dupuy and colleagues
also noted that PDGF did not modify heparin
binding or internalization, nor did it alter the
interaction of PDGF with target cells. It has been
reported that heparin and HS inhibited arterial SMC
proliferation in the presence of PDGF.4’18 The
present results confirm and expand these findings
with the observation that both HS and certain
species of heparin block the proliferation of
mesenchymal cells triggered by TGFfl and PDGF
(Table 2).
Heparin binds to growth factors including FGF,
endothelial cell growth factor, and PDGF.
19 The
interaction of heparin and FGF prolongs the
half-life of the growth factor, thus increasing its
availability to cells.2 Similar analyses have not yet
been made with HS. The binding of heparin to
growth factors may either prevent the growth
factor from interacting with cells, or, alternatively,
sequester it and present it to the cell thus
prolonging its eects, as was reported for FGF. In
contrast, our studies suggest that HS does not
inhibit proliferation by binding to growth factors
and preventing their interaction with cells. Even
when permitted only brief exposure to HS (prior to
treatment with serum or growth factors), the cells
retained the growth inhibitory effect (Table 3). This
is supported by the work of Reilly et al.3 who found
that heparin does not inhibit growth by preventing
serum mitogens or nutrients from interacting with
SMC. It is also possible that the HS is affecting cell
growth by interfering with the expression or aflqnity
of growth factor receptors. Some evidence suggests
that heparin down-regulates EGF receptors on rat
vascular SMC, but only when added late in the G1
phase of the cell cycle,
is In contrast, the number of
EGF receptors increases when rat cervical epithelial
cells were treated with heparin. The modulation of
growth factor receptor levels by HS has not been
examined.
Further evidence supporting the direct interac-
tion of GAGs with target cells includes the
observation that heparin has specific, high anity
to cell surface receptors. Vascular SMC contain
100 000 binding sites per cell that bind heparin with
a Kd of 10 -9 M. 3’9 In addition, heparin may exhibit
its inhibitory actions on BALB/c 3T3 cells by
blocking the expression of growth factor inducible
c-fos and c-myc expression. It is not known whether
HS works in this way.
In conclusion, the authors have found a HS
species which can inhibit the TGFfl and PDGF
induced proliferation of a variety of cell types
including Nor-10 SMC, 3T3 fibroblasts and
U2-osteosarcoma cell lines. Further research on the
molecular effects of HS on target cells will lead to
an understanding of how HS inhibits cell growth.
HS is not a strong anticoagulant, raising the
possibility of its use as a therapeutic agent to
prevent abnormal cell proliferation in diseases such
as atherosclerosis and pulmonary fibrosis.
References
1. Benitz W, Kelley R, Anderson C, Lorant D, Bernfield M. Endothelial
heparan sulfate proteoglycan. I. Inhibitory effects smooth muscle cell
proliferation. A J Respir Cell Mol Biol 1990; 2: 13.
2. Castellot J, Favreau L, Kamovsky M, Rosenberg R. Inhibition of vascular
smooth muscle cell growth by endothelial cell-derived heparin. J Biol Chem
1982; 257: 11256.
3. Reilly C, Fritze L, Rosenberg R. Heparin inhibition of smooth muscle cell
proliferation: cellular site of action. J Cell Physiol 1986; 129: 11.
4. Reilly C, Fritze L, Rosenberg R. Antiproliferative effects of heparin
vascular smooth muscle cells reversed by epidermal growth factor. J Cell
Physiol 1987; 131 149.
5. Reilly C, Kindy M, Brown K, Rosenberg R, Sonenshein G. Heparin prevents
vascular smooth muscle cell progression through the G1 phase of the cell
cycle. J Biol Chem 1989; 264: 6990.
6. Johnson E. Heparan sulphates from porcine intestinal Preparation
and physicochemical properties. Thromb Res 1984; 35: 583.
7. Jaques L. Heparin: unique misunderstood drug. Trends Pharmacol Sd 1982;
3: 289.
8. Kamijo R, TakedaK, Nagumo M, Konno K. Suppression of TNF-
stimulated proliferation of diploid fibroblasts and TNF-induced cytotoxicity
against transformed fibroblasts by TGF-fl. Biochem Biophys Res Commun 1989;
158: 155.
9. Castellot J, Wong K, Herman B, et al. Binding and internalization of heparin
by vascular smooth muscle cells. J Cell Phsiol 1985; 124: 13.
10. Castellot J, Cochran D, Kamovsky M. Effect of heparin vascular smooth
muscle cells. I. Cell metabolism. J Cell Phsiol 1985; 124: 21.
11. Dupuy E, Rohrlich P, Tobelem G. Heparin stimulates fibroblasts growth
induced by platelet derived growth factor. Call Bio Int Re.p 1988; 12: 17.
12. Wright T, Pukac L, Castellot J, Karnovsky M, Levine R, Kim-Park H,
Campisi J. Heparin suppresses the induction of c-fo and c-mc mRNA in
murine fibroblasts by selective inhibition of protein kinase C-dependent
pathway. Proc Natl Acad Sci USA 1989; 86: 3199.
13. Benitz W, Lessler D, Coulson J, Barnfield M. Heparin inhibits proliferation
of fetal vascular smooth muscle cells in the absence of platelet-derived growth
factor. J Cell Phjsio11986 127: 1.
14. Lidholt K, Kjellen L, Lindahl U. Biosynthesis of heparin: relationship
between the polymerization and sulphation processes. Biochem J 1989; 261:
999.
15. Wright T, Castellot J, Petiou M, Lormeau J, Choay J, Karnovsky M.
Structural determinants of heparin’s growth inhibitory activity: inter-
dependence of oligosaccharide size and charge. J Biol Chem 1989; 264: 1534.
16. Castellot J, Wright T, Karnovsky M. Regulation of vascular smooth muscle
cell growth by heparin and heparan sulfates. Semin Thromb Hemost 1987; 13:
489.
17. Lippman M, Mathews M. Heparins: varying effects cell proliferation in
vitro and lack of correlation with anticoagulant activity. Fed Proc 1977; 36: 55.
18. Fager G, Hansson K, Ottosson P, Dahllof B, Bondjers G. Human arterial
smooth muscle cells in culture: effects of PDGF and heparin growth in
vitro. Exp Cell Res 1988; 176: 319.
19. Vannucchi S, Pasquali F, Chiarugi V, Ruggiero M. Internalization and
metabolism of endogenous heparin by cultured endothelial cells. Biochem
Biophys Res Commun 1986; 140: 294.
20. Damon D, Lobb R, D’Amore P, Wagner J. Heparin potentiates the action
of acidic fibroblast growth factor by prolonging its biological half-life. J Cell
Physiol 1989; 138: 221.
ACKNOWLEDGEMENTS. This work supported by ONR =N00014-89-
J-1130 and the Elsa U. Pardee Foundation.
Received 21 April 1993;
accepted in revised form 13 May 1993
302 Mediators of Inflammation. Vol 2. 1993